Local teenager diagnosed with Guillain-Barre syndrome questions COVID-19 vaccine after receiving first dose
Strongbridge Biopharma plc presents detailed results of the RECORLEV® phase 3 LOGIC study (levocetoconazole) for the treatment of endogenous Cushing’s syndrome at the Endocrine Society’s 2021 annual meeting (ENDO)
Cases of inflammatory syndrome linked to coronavirus in children increased after increase in the bay area
Holiday COVID-19 is blamed for the increase in cases of inflammatory syndrome in children in some US cities